http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2003503344-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate | 2000-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2003-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2003503344-A |
| titleOfInvention | Remedies |
| abstract | (57) Abstract: In a method of treating obesity and related morbidity in humans, there is provided a compound of formula I comprising its enantiomer and its pharmaceutically acceptable salt. Wherein R 1 and R 2 are independently H or methyl, and a therapeutically effective amount of a lipase inhibitor excluding orlistate, to a human in need of such treatment. Wherein the compound of formula I and the lipase inhibitor are administered simultaneously, separately or sequentially. |
| priorityDate | 1999-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 206.